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Abstract
Background: The inhibition of Breast Cancer 1 (BRCA1) expression sensitizes breast and ovarian cancer cells to
platinum chemotherapy. However, therapeutically relevant agents that target BRCA1 expression have not been
identified. Our recent report suggested the potential of the histone deacetylase (HDAC) inhibitor, M344, to inhibit
BRCA1 expression. In this study, we further evaluated the effect of M344 on BRCA1 mRNA and protein expression,
as well as its effect on cisplatin-induced cytotoxicity in various breast (MCF7, T-47D and HCC1937) and ovarian
(A2780s, A2780cp and OVCAR-4) cancer cell lines.
Results: With the addition of M344, the platinum-sensitive breast and ovarian cancer cell lines that displayed
relatively high BRCA1 protein levels demonstrated significant potentiation of cisplatin cytotoxicity in association
with a reduction of BRCA1 protein. The cisplatin-resistant cell lines, T-47D and A2780s, elicited increased
cytotoxicity of cisplatin with M344 and down regulation of BRCA1 protein levels. A2780s cells subjected to
combination platinum and M344 treatment, demonstrated increased DNA damage as assessed by the presence of
phosphorylated H2A.X foci in comparison to either treatment alone. Using Chromatin Immunoprecipitation, A2780s
and MCF7 cells exposed to M344 alone and in combination with cisplatin, did not demonstrate enhanced
acetylated Histone 4 at the BRCA1 promoter, suggesting an indirect effect on this promoter.
Conclusions: The enhanced sensitivity of HDAC inhibition to platinum may be mediated through a BRCA1-
dependent mechanism in breast and ovarian cancer cells. The findings of this study may be important in the
future design of clinical trials involving HDAC inhibitors using BRCA1 as a tumour biomarker.
Background
Epithelial ovarian cancer (OC) is the fifth leading cause
of cancer death in women and the most lethal gynecolo-
gic malignancy [1]. In spite of aggressive surgical cytore-
duction and combination platinum/paclitaxel
chemotherapy, over 75% of women with stage III/IV dis-
ease will relapse and succumb to their disease. Resis-
tance to platinum-based therapy is a primary obstacle in
the management of advanced OC and novel therapies
are required to enhance platinum chemotherapy and to
improve prognosis. Hereditary mutations in the Breast
Cancer 1 (BRCA1) tumor suppressor gene are associated
with a significant risk of developing breast and OC [2,3].
Although somatic mutations in BRCA1 are uncommon
in sporadic OC, BRCA1 dysfunction is frequently
observed [4]. Silencing of BRCA1, through promoter
methylation, decreased expression through gene deletion
(loss of heterozygosity), or dysregulation of related genes
in the Fanconi anemia/BRCA1 pathway, is believed to be
important in the pathogenesis of a significant proportion
of sporadic tumors [5].
Preclinical work has shown that the level of BRCA1
protein expression correlates with chemosensitivity [6],
and recent clinical data supports that BRCA1-deficient
OC patients have a better prognosis [4,7]. Low BRCA1
protein and mRNA expression has also been associated
with improved survival in breast cancer [8] and non-
small cell lung cancer [9]. The improved outcome in
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BRCA1-deficient tumors is believed to be due, in part,
to an increased sensitivity to DNA damaging che-
motherapeutics, such as cisplatin [5]. Cells that lack
BRCA1 have a deficiency in the repair of double strand
breaks by the conservative mechanism of homologous
recombination (HR) [10]. As a result, these cancer cells
are reduced to using error-prone pathways thereby lead-
ing to genomic instability and enhanced cisplatin cyto-
toxicity. Thus, BRCA1 has been regarded as a rational
therapeutic target to help overcome platinum resistance
in advanced and recurrent OC. However, in an era of
evolving molecular inhibitors, new therapeutic strategies
merit consideration.
The interaction between histone acetyl transferases
and histone deacetylase (HDAC) enzymes modulates
chromatin structure and transcription factor accessibil-
ity, resulting in changes in gene expression [11]. Inhibi-
tors of HDAC have pleiotropic effects on cell cycle
arrest, apoptosis, differentiation and inhibition of growth
and angiogenesis [12,13], and have emerged as promis-
ing new therapeutic agents in multiple cancers, includ-
ing those resistant to standard chemotherapy. Class I
HDAC isoforms are expressed at significantly higher
levels in OC compared to normal ovarian tissue [14],
and various HDAC inhibitors can prevent the growth of
OC cancer cells both in vitro and in vivo [15,16].
Furthermore, HDAC inhibitors promote the accumula-
tion of acetylated histones, resulting in a more relaxed
chromatin structure, with areas of loosely compacted,
and hence, more transcriptionally active chromatin that
is more prone to DNA double strand breaks [17]. In
this regard, HDAC inhibitors have also demonstrated in
the preclinical setting the ability to potentiate the effects
of DNA-damaging agents, such as ionizing radiation and
several chemotherapeutic agents such as topoisomerase
inhibitors, and platinum compounds [18]. This suggests
that HDAC inhibitors have synergistic potential to
enhance the treatment of recurrent OC. The evaluation
of HDAC inhibitors in phase I/II clinical trials, either as
a single agent or in combination with standard cytotoxic
chemotherapy, is ongoing in a wide range of malignan-
cies including OC [16,19].
Targeting BRCA1 as a therapeutic strategy merits
further study in the management of BRCA1-associated
malignancies such as breast and OC. The potent HDAC
inhibitor, M344, a synthetic amide analog of trichostatin
A, has demonstrated growth inhibition, cell cycle arrest
and apoptosis in human endometrial and OC cells [20].
M344 is structurally similar to SAHA (vorinostat),
which was approved for the treatment of cutaneous T-
cell lymphoma [21]. Our group has recently shown that
M344 sensitizes A2780 OC cells to platinum by decreas-
ing the mRNA and protein expression of BRCA1 [7].
Further validation is required to confirm HDAC
inhibition on BRCA1 and to explore potential mechan-
isms of M344 as a targeted agent of BRCA1. In this
study, we further evaluate the effect of the combination
of M344 and cisplatin on BRCA1 mRNA and protein
expression and on cisplatin sensitivity in various breast
and OC cell lines.
Material and methods
Cell Culture
The A2780s and A2780cp cell lines were kindly pro-
vided by Dr. B. Vanderhyden (Ottawa Hospital Research
Institute, Ottawa, ON, CAN), and the T-47D and
OVCAR-4 cell lines were donated by Dr. J. Bell (Ottawa
Hospital Research Institute). MCF7 and HCC1937 were
purchased from the American Type Culture Collection
(Rockville, MD). All cell lines were maintained in Dul-
becco’s-MEM (Media Services, Ottawa Hospital Regio-
nal Cancer Centre, ON, CAN) supplemented with 10%
fetal bovine serum (Wisent Inc., St-Bruno, QC, CAN)
and 100 μg/ml penicillin-streptomycin (Invitrogen,
Carlsbad, CA). Unless otherwise described, cells were
treated for 24 hrs with 2 μg/ml cisplatin (provided by
the pharmacy at the Ottawa Hospital Regional Cancer
Centre) alone, and in combination with the HDAC inhi-
bitor M344 (Biovision, Mountain View, CA) at concen-
trations of 0.5, 1.0, or 5.0 μM. Phase contrast images
were collected using the 10 × objective of an Eclipse
TE2000-U (Nikon Canada Inc., Mississauga, ON, CAN).
Western Blotting
Protein samples were collected in RIPA buffer (50 mM
Tris-Cl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 0.25% sodium deoxycholate, 0.1% SDS) contain-
ing 1X Protease Inhibitor Cocktail (Sigma-Aldrich, St-
Louis, MO) and protein content was quantified using a
commercially available protein assay (BCA Protein
Assay Kit, Pierce, Rockford, IL) and a Biomate3 Spectro-
photometer (Thermo Fisher Scientific, Waltham, MA).
Samples were separated on 8-12% SDS polyacrylamide
gel and transferred to a PVDF membrane (Immobilon-
P, Millipore, Billerica, MA). Blocking was carried out
with 5% milk in Tris-buffered saline with Tween-20
(TBS-T). For all subsequent immunoblotting, antibodies
were diluted to the appropriate concentration in 5%
milk in TBS-T. Blots were incubated with the following
primary antibodies for 1 hr at room temperature or
overnight at 4°C: mouse-anti BRCA1 (1:200, D-9, Santa
Cruz, Santa Cruz, CA), rabbit-anti acetylated Histone 4
(acetyl H4) (1:1000, Upstate Cell Signaling, Lake Placid,
NY), and mouse-anti actin (1:5000, Sigma-Aldrich). Fol-
lowing 3 washes in TBS-T, blots were incubated with
the appropriate horseradish peroxidase (HRP)-labeled
secondary antibody (goat-anti-rabbit-HRP, goat-anti-
mouse-HRP, 1:5000, Jackson ImmunoResearch, West
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Grove, PA) for 1 hr at room temperature. The chemilu-
minescent substrate used was Supersignal West Pico
(Pierce) and the visualization of the protein bands was
performed using the GeneSnap image acquisition system
followed by densitometry analysis with the GeneTools
software (Syngene, Frederick, MD).
RNA isolation and reverse transcriptase polymerase chain
reaction (RT-PCR)
Total RNA was extracted from cell lines in sub-conflu-
ent 10 cm dishes using the RNeasy® kit (Qiagen, Ger-
mantown, MD). RNA concentration was quantified
using a NanoDrop ND-1000 spectrophotometer
(Thermo Scientific Inc, Wilmington, DE). Total RNA (1
μg) was reverse-transcribed. The Applied Biosystems AB
7500 Real-Time PCR system (Applied Biosystems, Foster
City, CA) was used to detect amplification. A real-time
PCR reaction was carried out in a total volume of 25 μl
that contained 2.5 μl of synthesized cDNA, 1.25 μl of
TaqMan Gene Expression Assay Primer/Probe (20X)
(Applied Biosystems, BRCA1, HS00173233), 12.5 μl of
TaqMan Universal PCR Master Mix (2X) (Applied Bio-
systems) and 8.75 μl of RNase-free water for BRCA1
expression. GAPDH (Applied Biosystems, HS4333764-F)
was used as an endogenous control. Amplification con-
ditions were 95°C for 5 min, 40 PCR cycles at 95°C for
15 sec, and 60°C for 1 min. Three independent reactions
from separate RNA extractions were used to determine
the average RNA expression and a standard error for
each treatment condition.
Cell Viability Assay
Cell viability was measured by the methylthiazolyldiphe-
nyl-tetrazolium bromide (MTT) rapid colorimetric
assay. Approximately 4,500 cells were seeded into each
well of a 96-well flat bottom plate. The cells were incu-
bated overnight to allow for cell attachment. Cells were
then treated with cisplatin in concentrations of 0-8 μg/
ml alone or in combination with 1 μM of the HDAC
inhibitor, M344. Forty eight hours following treatment,
42 μl of a 5 mg/ml MTT substrate (Sigma-Aldrich)
solution in phosphate buffered saline (PBS) was added
and incubated for up to 4 hrs at 37°C. The resulting vio-
let formazan precipitate was solubilized by the addition
of 82 μl of a 0.01 M HCl/10% SDS (Sigma-Aldrich)
solution and plates were incubated overnight at 37°C.
The plates were then analyzed on an MRX Microplate
Reader (Dynex Technologies, Chantilly, VA) at 570 nm
to determine the optical density of the samples.
Flow Cytometric Analysis of Apoptosis
Cells treated for 24 hrs in 10 cm dishes were fixed in
80% ethanol for 1 hr. Cells were then washed with PBS
and resuspended in staining buffer (0.2% Triton X-100,
1 mM EDTA in PBS, pH7.4), containing 25 μg/ml pro-
pidium iodide (Sigma-Aldrich) and 100 μg/ml RNaseA
(Sigma-Aldrich). Cells were incubated with staining buf-
fer in the dark for 1 hr prior to DNA quantification by
the Coulter Epics XL flow cytometer (Beckman Coulter,
Fullerton, CA). Data analysis was performed using Mod-
Fit LT (Verity Software House Inc., Topsham, ME).
Immunofluorescence
Cells were fixed on gelatin-coated coverslips in cold
methanol at -20°C for 1 hr, followed by 3 washes in 1 ×
PBS. The cells were then permeabilized via incubation
with 0.2% Triton-X-100 in PBS for 10 min, followed by
3 washes in PBS. Blocking was carried out for 30 min at
room temperature with 5% normal goat serum in PBS.
Cells were incubated with mouse anti-H2A.X (ser139)
(1:100 in PBS, Millipore) for 1 hr, followed by 3 PBS
washes. Secondary antibody, anti-mouse Alexa Fluor
488, (1:400 in PBS, Invitrogen) was applied for 1 hr, fol-
lowed by 3 washes in PBS. Following a rinse with
ddH2O, coverslips were mounted on glass slides using
Vectashield mounting medium with DAPI (Vector
Laboratories, Burlington, ON, Canada). Fluorescence
was assessed using the Axioskop 2 MOT microscope
(Carl Zeiss MicroImaging, Thornwood, NY).
Flow Cytometric Analysis of g-H2A.X Expression
Following treatment, cells were trypsinized, washed in
PBS and fixed on ice with 1% paraformaldehyde for 15
min. After centrifugation, the cell pellet was resus-
pended in 500 μl of PBS and transferred to a tube con-
taining 4.5 ml of cold 70% ethanol and kept at -20°C for
a minimum of 2 hrs. Cells were centrifuged and then
washed twice in BSA-T-PBS (1% bovine serum albumin
and 0.2% Triton-X-100 in 1 × PBS). Following the sec-
ond wash, the cell pellet was resuspended in BSA-T-
PBS containing mouse anti-gamma H2A.X (ser139)
(Millipore) primary antibody at 1:100 and incubated
overnight at 4°C. Cells were then washed once in BSA-
T-PBS and resuspended in BSA-T-PBS containing anti-
mouse Alexa Fluor 488 (Invitrogen) secondary antibody
at 1:400 and incubated at room temperature in the dark
for 1 hr. Cells were washed once in BSA-T-PBS and
resuspended in PBS containing 50 μg/ml propidium
iodide (Sigma-Aldrich) and 5 μg/ml RNAse A (Sigma-
Aldrich). Cells were analyzed on a Coulter Epics XL
flow cytometer (Beckman Coulter) and the resulting
data was assessed using ModFit software (Verity Soft-
ware House).
Chromatin Immunoprecipitation (ChIP) Assay
Cells were fixed in 1% formaldehyde (BDH, VWR
International, Mississauga, ON, CAN) for 20 min at
room temperature. Fixation was stopped by quenching
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with 2.5 mM glycine solution to a final concentration
of 200 mM for 5 min. Cells were then washed twice
with ice-cold PBS and harvested in 1 ml cold PBS by
centrifugation for 5 min at 5,000 rpm. The pellet was
resuspended in 90 μl lysis buffer (50 mM Tris-HCl pH
8.0, 10 mM EDTA pH 8.0, 1% SDS) supplemented
with 1X Protease Inhibitor Cocktail (Sigma-Aldrich), 1
mM 1,4-dithio-DL-threitol (DTT) (Sigma-Aldrich), and
1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-
Aldrich). The lysates were sonicated using a Sonicator
3000 (Misonix, Farmingdale, NY) to shear DNA to an
average size of 300 to 1000 base pairs and then cleared
of debris by centrifugation at 14,000 rpm for 15 min.
Input controls were removed from each sample and
stored at -20°C.
The sonicated lysates were diluted 10-fold with dilu-
tion buffer (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2
mM EDTA pH 8.0, 1% Triton X-100), supplemented
with 1X Protease Inhibitor Cocktail, 1 mM DTT and 1
mM PMSF, and immunoprecipitated by overnight rota-
tion at 4°C with rabbit-anti acetyl H4 (1:200, Millipore)
primary antibody. Negative controls were incubated in
the absence of primary antibody. Immune complexes
were collected by 2 hr rotation at 4°C with the addi-
tion of 40 μl of protein A agarose/salmon sperm DNA
50% slurry (Millipore) to both positive samples and
negative controls. The beads were pelleted gently by
centrifugation for 1 min at 3,000 rpm at 4°C and
washed with 1 ml of the following buffers by rotation
for 10 min at 4°C: Buffer A (low salt; 0.1% SDS, 1%
Triton X-100, 20 mM Tris-HCl pH 8.0, 2 mM EDTA
pH 8.0, 150 mM NaCl) once, Buffer B (high salt; 0.1%
SDS, 1% Triton X-100, 20 mM Tris-HCl pH 8.0, 2
mM EDTA pH 8.0, 500 mM NaCl) once, Buffer C (1%
NP-40, 1% sodium deoxycholate, 20 mM Tris-HCl pH
8.0, 1 mM EDTA pH 8.0, 0.25 M LiCl) once and TE
washing buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA
pH 8.0) twice. All antibody complexes were eluted
with 400 μl freshly prepared elution buffer (1% SDS,
100 mM NaCHO3) by rotating at room temperature
for 30 min. Cross-links were reversed by overnight
incubation with 100 μg proteinase K (Roche Diagnos-
tics, Laval, QC, CAN) at 65°C.
DNA was purified using a QiaQuick PCR Purification
Kit (Qiagen) according to the manufacturer’s instruc-
tions. Quantitative PCR was performed using a Roche
LightCycler Version 3 (Roche Diagnostics) for 40 cycles
of amplification. The binding of acetyl H4 to the
BRCA1 proximal promoter region was determined using
the following primer pair: forward TTTCCTTTTACGT-
CATCCGGG and reverse GCTAAGCAGCAGCCTCT-
CAGA [22]. PCR products were resolved on 1.6%
agarose gels.
Results
Expression of BRCA1 in a panel of breast and ovarian
cancer cell lines
Three breast cancer cell lines (MCF7, T-47D, and
HCC1937) and three OC cell lines (A2780s, A2780cp, and
OVCAR-4) were chosen for analysis due to their varying
degree of sensitivity to cisplatin treatment (Figure 1A).
Consistent with other reports, T-47D and A2780cp
demonstrated cisplatin resistance, whereas MCF7,
HCC1937, A2780s, and OVCAR-4 displayed a range of
sensitivity to cisplatin treatment [23,24]. The basal level of
BRCA1 protein expression was analyzed by Western blot
(Figure 1B). MCF7 displayed the most significant level of
BRCA1 protein expression of the breast cancer cell lines
and was assigned a value of 1.0. As expected, HCC1937
cells, which harbor the germ line BRCA1 frame shift
mutation 5382insC, leading to a premature stop codon
and a truncated non-functional protein [25], did not dis-
play detectable BRCA1 protein. A2780s cells expressed the
highest level of BRCA1 protein of the OC cell lines, but
only slightly more than their cisplatin-resistant counter-
part, A2780cp. All cell lines were evaluated by RT-PCR for
BRCA1 mRNA expression with varying levels shown (Fig-
ure 1C). HCC1937 cells demonstrated detectable levels of
BRCA1 mRNA, albeit lower than the other breast cancer
cell lines examined, which is in keeping with the previous
observation that tumors from germ line mutation carriers
express mRNA levels lower than in sporadic tumors [26].
Overall, variable levels of BRCA1 mRNA and protein were
detected in the ovarian and breast cancer cell lines ana-
lyzed which is consistent with the range of expression
levels previously observed in ovarian and breast tumor
specimens [4,7,27].
M344 reduces BRCA1 mRNA and protein expression in
breast and OC cell lines
BRCA1 mRNA levels were determined by RT-PCR fol-
lowing exposure to increasing concentrations of the
HDAC inhibitor M344 alone and in combination with
cisplatin in all 6 cell lines evaluated in this study (Figure
2). With increasing concentrations of M344, there was a
dose dependant decrease in BRCA1 mRNA and treat-
ment with both 1 and 5 μM concentrations of M344
resulting in a significant decrease in BRCA1 expression
in all cell lines examined. M344 in combination with
cisplatin led to a decrease in BRCA1 mRNA expression
as compared to cisplatin treatment alone in all cell lines
with the exception of A2780s, which is recognized as
having potent cytotoxicity to cisplatin.
The effect on BRCA1 protein expression of M344
alone, and in combination with cisplatin, was assessed
by Western blot analysis (Figure 3). Since OVCAR-4 has
no measurable BRCA1 protein and HCC1937 has a
Weberpals et al. Cancer Cell International 2011, 11:29
http://www.cancerci.com/content/11/1/29
Page 4 of 13
truncated labile protein, these two cell lines were
excluded from this analysis. Of the four remaining cell
lines, BRCA1 protein levels decreased with increasing
dose of M344. In the MCF7 cell line, BRCA1 was down
regulated at physiological doses of M344 (0.5 μM and
1.0 μM) but M344 does not have the same inhibitory
effect on BRCA1 at the 5.0 μM dose. Co-treatment with
cisplatin and increasing concentrations of M344 reduced
BRCA1 protein levels in all breast and ovarian cell lines
examined.
M344 enhances cisplatin sensitivity and increases
apoptosis in breast and OC cells
The MTT assay was employed to determine the effects
on cell viability following treatments with M344 (1 μM,
24 hrs) alone and in combination with cisplatin (2 μg/
ml, 24 hrs) (Figure 4A). Of interest, the BRCA1 expres-
sing cell lines (MCF7, T47D, A2780s, A2780cp) demon-
strated co-operative cytotoxicity with M344 and
cisplatin combination treatments (P < 0.001, cisplatin
treatment compared to combination). However, discern-
able effects on cytotoxicity with this combination treat-
ment were observed in the BRCA1-deficient cells,
HCC1937 and OVCAR4. Among the cisplatin-resistant
cell lines (T-47D and A2780cp), as expected, there was
little effect on cell death with the addition of 2 μg/ml
cisplatin. The addition of the HDAC inhibitor resulted
in greater overall cytotoxicity and proved to be more
effective than cisplatin treatment alone (P < 0.001).
Thus, co-treatment with M344 was able to potentiate
the effects of cisplatin in breast and OC cells coincident
with the ability of M344 to target BRCA1 expression.
To assess the therapeutic effect on apoptosis, two OC
cell lines (A2780s and A2780cp) were treated with
M344 and cisplatin, alone or in combination, and sub-
jected to flow cytometric analysis (Figure 4B). Treatment
with HDAC inhibitor did not cause a marked increase
in apoptosis versus control cells, while cisplatin treat-
ment displayed evidence of S/G2 phase arrest in the cis-
platin sensitive A2780s cell line. The combination of
M344 and cisplatin displayed an apoptotic response as
demonstrated by the emergence of a sub-G1 peak char-
acteristic of the nuclear and cellular fragmentation asso-
ciated with this mode of cell death.
Co-treatment with the HDAC inhibitor M344 enhanced
cisplatin-induced gH2A.X foci formation
We further characterized the morphologic changes asso-
ciated with combination treatment. Phase contrast
images of A2780s cells are presented after 24 hrs of
treatment in Figure 5A. Cells exposed to M344 and cis-
platin showed characteristic features consistent with
apoptosis, including cell rounding and detachment.
Figure 1 Cisplatin sensitivity and BRCA1 expression in the
breast and ovarian cancer derived cell lines evaluated in this
study. A) MTT cell viability assays comparing the responses of a
panel of cell lines to 2 μg/ml cisplatin. Cell viability was assayed
with the activity of untreated cells taken to be 100%. Values
represent the mean +/- SEM of three separate experiments. B)
Western blot analysis of basal expression levels of BRCA1 protein in
a panel of cell lines. Actin was employed as a loading control.
Numbers indicate protein densitometry readings with MCF7 used as
the calibrator and set to 1.0. The experiment was repeated with
similar results. C) Basal levels of BRCA1 mRNA analyzed by RT-PCR.
Relative expression for each cell line was calculated following
normalization to GAPDH levels and then further normalized to MCF-
7 for ease of comparison and expressed as the mean +/- SEM of
three separate experiments.
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A hallmark of DNA double strand breaks, including
those induced by cisplatin, is the formation of gH2A.X
foci, resulting from the rapid phosphorylation of H2A.X
at sites of DNA damage [28]. Following M344 +/- cis-
platin treatment, A2780s cells were evaluated for gH2A.
X foci formation using direct immunofluorescence (Fig-
ure 5B). Cells treated with DMSO control did not dis-
play gH2A.X foci and there was minimal gH2A.X foci
formation with exposure of 5 μM M344 for 24 hrs.
These findings suggest that treatment with single agent
HDAC inhibitor was not sufficient to induce significant
DNA damage. As expected, the majority of cells dis-
played many foci when treated with cisplatin alone.
However, the addition of M344 to cisplatin resulted in a
greater intensity of gH2A.X staining, which likely reflects
an increase in DNA double strand breaks. Treated cells
were also sorted via flow cytometry after being incu-
bated with a fluorescent-labeled anti-gH2A.X antibody
(Additional File 1). Treatment with the M344/cisplatin
combination compared to cisplatin alone resulted in a
greater percentage of cells with labeled gH2A.X.
Decreased acetylated Histone 4 at the BRCA1 proximal
promoter region following M344 treatment
A ChIP assay was performed in order to investigate
whether M344 causes a direct change in BRCA1 gene
expression by modulation of the chromatin structure of
the BRCA1 promoter. MCF7 and A2780s cells were
treated for 24 hrs with M344 (5 μM) and cisplatin (2
μg/ml), both individually, and in combination (Figure 6
and Additional File 2). With cisplatin treatment, there
was an increase in BRCA1 DNA bound to acetylated
histones. This supports previous reports that an increase
in BRCA1 expression is reflective of the activation of
the DNA damage response triggered by platinum agents
[29]. The amount of BRCA1 DNA bound to acetylated
histones decreased with the addition of this HDAC inhi-
bitor to cisplatin, indicating that transcriptional
Figure 2 Effect of M344 and cisplatin treatments on the levels of BRCA1 mRNA in our panel of cell lines. BRCA1 mRNA levels were
analyzed by RT-PCR following 24 hrs of treatment with 0.5, 1.0, or 5.0 μM M344 either alone or in combination with 2 μg/ml cisplatin. DMSO is
the solvent control for the M344 treatment and 2 μg/ml cisplatin is the control for the combination. Values represent the mean +/- SEM of three
separate experiments. Statistically significant differences, when present, between 5 μM M344 and DMSO control or 2 μg/ml cisplatin + 5 μM
M344 and 2 μg/ml cisplatin alone are indicated by * where P < 0.05, ** where P < 0.01, and *** where P < 0.001.
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repression may also be occurring in the combination
treatment consistent with the RT-PCR and Western blot
data in Figures 2 and 3.
Discussion
BRCA1-deficient tumors have been shown to be more
responsive to platinum-based chemotherapy, but as of
yet, there is no molecular target of BRCA1 that can
potentiate platinum sensitivity in OC patients. Prior
work in our lab has demonstrated that co-treatment of
OC cells, A2780s/cp, with the HDAC inhibitor M344
enhanced sensitivity to cisplatin [7]. In the present
study, we further validate this finding in select breast
and OC cell lines that differentially express BRCA1. The
platinum-sensitive breast (MCF7) and OC (A2780s) cell
lines, which displayed relatively high BRCA1 protein
levels, displayed significant potentiation of cisplatin
cytotoxicity in association with a reduction of BRCA1
protein with the addition of M344. Tumor cell lines
with relatively low levels of BRCA1 protein (HCC1937,
OVCAR-4) displayed inherent platinum sensitivity, and
no significant enhancement of cisplatin was observed
with the addition of the HDAC inhibitor. T-47D and
A2780cp, cell lines known to be resistant to cisplatin,
also elicited enhanced cytotoxicity of cisplatin with the
addition of M344 in association with down regulation of
BRCA1 protein, suggesting the potential of HDAC inhi-
bition to enhance platinum sensitivity through a
BRCA1-mediated mechanism.
The present study supports work by Burkitt and
Ljungman [30], which showed that the HDAC inhibitor
phenylbutyrate sensitized cisplatin-resistant head and
neck cancer cell lines to cisplatin mediated by the abro-
gation of the Fanconi anemia/BRCA pathway. Phenylbu-
tyrate was found to inhibit the formation of FANCD2
nuclear foci in conjunction with cisplatin and this corre-
lated with down regulation of BRCA1. Furthermore,
Zhang’s group demonstrated that trichostatin A expo-
sure delayed DNA damage repair in response to ionizing
radiation by the suppression of key genes including
BRCA1 [31]. A recent study by Kachhap et al. showed
that valproic acid potentiated the sensitivity of prostate
cancer cells to cisplatin through down regulation of HR
repair and DNA damage response genes such as BRCA1
Figure 3 Effect of M344 and cisplatin treatments on the levels of BRCA1 protein expression in our panel of cell lines. Western blot
analysis of BRCA1 following 24 hrs of treatment with 0.5, 1.0, or 5.0 μM M344 either alone or in combination with 2 μg/ml cisplatin. DMSO is
the solvent control for the M344 treatment and 2 μg/ml cisplatin is the control for the combination treatment. The experiment was repeated
with similar results. Densitometry readings are normalized to the DMSO solvent control.
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[32]. The decrease in BRCA1 gene transcription was due
to a reduction in binding of the activating protein, E2F1,
to the BRCA1 promoter. In the same prostate cancer
cell line model, a new HDAC inhibitor, H6CAHA, sup-
pressed the expression of BRCA1 mRNA, and when
used in combination with g-radiation, prevented the
growth of tumor xenografts [33].
The sensitizing properties of HDAC inhibitors to
DNA damaging agents has been linked to aberrant dou-
ble strand break repair and cellular stress signaling [34].
Figure 4 Analysis of the cytotoxic and apoptotic effects of the combination of M344 and cisplatin inn this cell line panel. A) MTT cell
viability assays comparing the responses of a panel of cell lines to 1 μM M344 alone, 2 μg/ml cisplatin alone or both treatments in combination
for 48 hrs. Cell viability was assayed with the activity of untreated cells taken to be 100%. Values represent the mean +/- SEM of three separate
experiments. Differences between treatment with cisplatin alone versus treatment with the cisplatin and M344 combination were analyzed using
paired T-test analyses. * indicates a significant difference where P < 0.001. B) Percentage of apoptotic cells in the A2780s cell line following 24
hrs of treatment and A2780cp cell line following 48 hrs treatment with 1.0 μM M344 alone or in combination with 2 μg/ml cisplatin as assessed
by flow cytometry. The experiment was done in three replicates with similar results.
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The present study confirms reports that HDAC inhibi-
tion, in combination with DNA damaging agents,
increases the phosphorylation of H2A.X, a known mar-
ker of DNA double strand breaks [35-37]. A study con-
ducted in a metastatic breast cancer cell line provides
evidence of increased phosphorylation of H2A.X and
enhanced sensitivity to vorinostat in combination with
radiation [38]. In both human glioma and prostate can-
cer cells, vorinostat reduced DNA-dependent protein
kinase (DNA-PK) and Rad 51, two critical components
of DNA double strand break repair machinery [39]. In
the human melanoma cell line, A375, vorinostat sensi-
tized cells to radiation-induced apoptosis by inhibiting
key DNA repair genes, Ku70, Ku80 and Rad 50 [37].
Using cDNA expression arrays, phenylbutyrate attenu-
ated the expression of DNA-PK and worked synergisti-
cally with ionizing radiation to induce apoptosis in
prostate cancer cell lines [34].
BRCA1 has many diverse functions in the cell includ-
ing transcriptional control through modulation of chro-
matin structure as BRCA1 is known to interact with the
SWI/SNF chromatin remodeling complex [40]. The
BRCA1-SWI/SNF complex is believed to be essential for
the activation of genes involved in the DNA damage
response and this complex has a direct role in HR by
enabling access to sites of DNA damage. The BRCA1 C-
terminal (BRCT) domain of the BRCA1 protein associ-
ates with both HDAC1 and HDAC2, and prior studies
suggest that this association directly represses transcrip-
tion [41]. In this study, the ChIP assay demonstrated
that the amount of BRCA1 promoter DNA containing
acetylated histones was decreased following M344 and
cisplatin combination treatment relative to controls.
This result suggests that BRCA1 is not a direct target of
M344 activity, but that M344 may enhance the expres-
sion or activity of a transcriptional repressor of BRCA1.
As an example, the Inhibitor of DNA binding (ID)-4 is a
dominant negative transcriptional regulator [42], which
has been shown to repress the BRCA1 promoter [43].
Studies have identified an inverse correlation between
ID4 and BRCA1 mRNA and protein expression levels in
breast and ovarian tumour tissue [44,45]. Further studies
are needed to evaluate ID4’s role in BRCA1 transcrip-
tional activity and as a potential marker of BRCA1
expression.
Both in vitro and in vivo studies have demonstrated
cytotoxic efficacy of single agent HDAC inhibitors in
OC [14,20,46,47] and breast cancer [48,49] cell models.
In our study, increasing doses of the HDAC inhibitor
M344 down regulated BRCA1 protein expression in all
Figure 5 Evaluating the effect of M344, cisplatin and their
combination on the formation of gH2A.X foci. A) Phase contrast
images of A2780s cells following 24 hrs of treatment with 5.0 μM
M344 alone or in combination with 2 μg/ml cisplatin. B) A2780s
cells subjected to combination platinum and M344 24 hr treatment
demonstrates increased levels gH2A.X foci detected by
immunoflourescence. Repeat of the experiment showed similar
findings.
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cell lines examined except for the highest dose in MCF7
breast cancer cells. This could be due to a negative feed-
back loop involving the BRCA1 and HDAC1 proteins
complexing with CtBP (C terminal-binding protein) on
the BRCA1 promoter to inhibit its transcription [50]. A
significant alteration in HDAC1 function and BRCA1
protein levels by the HDAC inhibitor M344 could allevi-
ate the repression and cause an upregulation of BRCA1
transcription and subsequent protein expression. Since
there is limited data in breast and ovarian cancer, stu-
dies conducted in other tumor cell models suggest the
combination of HDAC inhibitors and DNA-targeted
agents is a rational therapeutic approach in the treat-
ment of OC. In the human oral squamous cell carci-
noma cell line, HSC-3, SAHA enhanced cisplatin-
induced apoptosis [51]. The study by Chen et al. [52]
demonstrated a histone deacetylation-independent
mechanism whereby HDAC inhibitors sensitized pros-
tate cancer cell lines to DNA-damaging chemotherapeu-
tic drugs, bleomycin, doxorubicin and etoposide. In
their study, pretreatment of prostate cancer cells with
HDAC inhibitors led to increased acetylation of Ku70
and impaired Ku70 function in repairing DNA double
strand breaks resulting in enhance cell killing via a
DNA repair-mediated mechanism. The HDAC inhibitor,
PCI-24781, after treatment of Hodgkin and non-Hodg-
kin lymphoma cells with a PARP inhibitor, resulted in a
synergistic increase in apoptosis and a decrease in
RAD51 expression [53].
Recent clinical trials have evaluated HDAC inhibitors
in solid tumors, both as a single agent and in
combination with chemotherapy. A phase II study con-
ducted by the Gynecologic Oncology Group, examined
oral vorinostat in the treatment of persistent or recur-
rent epithelial ovarian or primary peritoneal carcinoma
in patients who were platinum resistant/refractory
(progression-free interval < 12 months) [16]. In the
twenty-seven women enrolled, the incidence of signifi-
cant toxicity was low, but only two had a progression-
free interval over 6 months. A better response was
seen in a phase II study combining valproic acid, the
demethylating agent hydralazine, and chemotherapy in
various resistant solid tumors including breast and
ovarian cancer [54]. Twelve of fifteen patients (80%)
overcame resistance to chemotherapy and showed
either partial response or stable disease, although some
hematologic toxicity was observed. A phase I study of
vorinostat in combination with carboplatin and pacli-
taxel for advanced solid malignancies showed that the
oral drug was well tolerated with eleven and seven of
twenty-five patients analyzed demonstrating a partial
response and stable disease, respectively, and encoura-
ging anticancer activity in patients with previously
untreated NSCLC [19]. A Phase I/II study of paclitaxel
plus carboplatin in combination with vorinostat is cur-
rently underway in Denmark for patients with
advanced, recurrent, platinum-sensitive epithelial OC
(http://ClinicalTrials.gov, Identifier: NCT00772798).
Further trials with correlative studies focusing on the
BRCA1 pathway are needed to define a subset of the
patient population which is most responsive to HDAC
inhibitors.
Figure 6 ChIP analysis of the levels of acetylated histones at the BRCA1 promoter following M344 and cisplatin treatments. A) MCF7
and B) A2780s cells treated with 5.0 μM M344 in combination with 2 μg/ml cisplatin for 24 hrs show reduced amounts of BRCA1 promoter DNA
bound to acetylated histone 4 (AcH4). Real-time PCR products were run on a 1.6% agarose gel. “Input” controls: untreated; “No Ab” controls:
incubation with agarose beads in the absence of aAcH4; and “aAcH4": incubation with agarose beads and aAcH4. The experiment was
repeated twice with similar results.
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There are several limitations to this study which merit
consideration. Firstly, we recognize that studying the
mechanism of BRCA1 down regulation by an HDAC inhi-
bitor exclusively in cancer cell lines provides limited data
that requires further exploration in an in vivo model. This
will allow the involvement of extracellular components,
such as the hormone estrogen, which has been shown to
play a role in BRCA1 function [55]. Secondly, we and
others have observed a lack of correlation between the
BRCA1 mRNA and protein levels. This can be partly
explained by the expression level of BRCA1 which oscil-
lates with the cell-cycle and is regulated by both transcrip-
tion and protein stability [56]. BRCA1 protein can be
degraded by BARD1 in S-phase through the ubiquitin pro-
teolysis pathway, thus unbalancing the mRNA to protein
ratio [57]. Discrepancies between BRCA1 mRNA and pro-
tein can also be due to experimental limitations. Western
blot analysis using the C-terminal BRCA1 antibody cap-
tures all splice variants of the gene [58] but is unable to
detect truncated forms [59]. Furthermore, BRCA1 Δ11b, a
splice variant abundantly expressed in many cells,[60] is
not captured by the primers designed to cross the exon
11-12 boundary, which are used to measure mRNA levels
by RT-PCR in our study. Thirdly, we propose that the
enhanced sensitivity to cisplatin seen by HDAC inhibition
is mediated though a BRCA1 mechanism although we are
unable to provide direct evidence for this correlation.
However, there is evidence in other reports that BRCA1
plays an essential role in inducing apoptosis in response to
DNA-damaging agents in breast cancer cell line models.
Inhibiting BRCA1 protein in MCF-7 cells increased cispla-
tin sensitivity [29] and depleted BRCA1 protein expression
by siRNA-inhibited activation of the apoptotic pathway in
response to DNA-damaging treatment [6]. Furthermore,
BRCA1 transcription is known to be activated by the tran-
scription factor E2F1 [61]. E2F1 protein levels were
depleted with valproic acid exposure in prostate cancer
cell lines and valproic acid reduced E2F1 binding to the
BRCA1 promoter, thus providing insight into a mechan-
ism for the down regulation of the BRCA1 gene by HDAC
inhibition.
This study suggests that treatment with an HDAC
inhibitor enhances the cytotoxicity of cisplatin therapy
in ovarian and breast cancer cells and that this increased
sensitivity may be mediated by a BRCA1 mechanism.
The potentiation of platinum with an HDAC inhibitor
may be a novel therapeutic option for advanced or
recurrent OC patients with tumors expressing signifi-
cant levels of BRCA1.
Additional material
Additional file 1: Evaluating the effect of M344, cisplatin and their
combination on the gH2A.X expression by FACS analysis. A2780s
cells were treated with 1 μM M344, 2 μg/ml of cisplatin alone, and in
combination, for 24 hrs. Cells were labelled with an anti-gH2A.X antibody
and evaluated for fluorescent levels by flow cytometry that showed an
increase in the proportion of cells with increased gH2A.X staining in the
combination.
Additional file 2: ChIP analysis of the levels of acetylated histones
at the p21 promoter following M344 and cisplatin treatments. MCF7
cells treated with 5.0 μM M344 and 2 μg/ml cisplatin alone, and in
combination for 24 hrs were subjected to ChIP analysis. AcH4 antibody
was used for the immunoprecipitation. p21 promoter primers were used
to quantify the DNA by PCR, which was then normalized to Input
controls. Values represent the mean +/- SEM of two separate
experiments.
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